US equities |
SPCX $168.40 ▲+5.94% NVDA $237.34 ▲+1.45% MU $1,066.97 ▼-0.74% TSLA $378.86 ▲+2.23% MSFT $525.58 ▲+1.56% SNDK $1,714.97 ▼-0.29% INTC $117.23 ▼-1.76% META $743.39 ▲+2.10%
FinancialContent

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

12.35 +0.09 (+0.73%)
Delayed Quote Updated: 1:16 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta ↗
Ark Invest's Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Medicine, UiPath, Ibotta, Roblox, Repare Therapeutics, and CareDx. 
Via Benzinga
News headline image
What Analysts Are Saying About Intellia Therapeutics Stock ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Intellia Therapeutics? ↗
 
Via Benzinga
News headline image
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Intellia Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FMC, Elastic, Intellia, and Merck and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Intellia Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Wall Street's Top 10 Stock Calls This Week - Saturday, March 1 ↗
Via Talk Markets
Topics Stocks / Equities
News headline image
ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Intellia Therapeutics Delivers a Q4 Beat ↗
Intellia Therapeutics reported better-than-expected results for the fourth quarter thanks to a boost in its collaboration revenue. 
Via The Motley Fool
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Edison, Elastic, Intellia, and Merck and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Intellia Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street ↗
Via The Motley Fool
News headline image
NTLA Investors are Suing Intellia Therapeutics, Inc.; Contact Robbins LLP for More Information
From Robbins LLP
Via GlobeNewswire
News headline image
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Intellia Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
INTELLIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Intellia Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Intellia Therapeutics, Inc. Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against NTLA
From Robbins LLP
Via GlobeNewswire
News headline image
Rosen Law Firm Urges Intellia Therapeutics, Inc. (NASDAQ: NTLA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From Rosen Law Firm
Via Business Wire
News headline image
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) INVESTOR ALERT: Investors With Large Losses in Intellia Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens ↗
The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >